"The purpose of the clinical study is to assess the safety, tolerability and immunogenicity of the drug" Gam-COVID-Vac "in the dosage form" nasal spray "with the participation of adult volunteers," the document says.
As specified, the study, which will involve 500 volunteers, will end on December 31, 2023.
In August, the director of the Gamaleya Research Center for Epidemiology and Microbiology, Alexander Gintsburg, announced the completion of preclinical studies of a nasal vaccine against coronavirus and readiness to move to clinical trials.